About Jnana therapeutics
Jnana Therapeutics: Revolutionizing Drug Discovery and Development
Jnana Therapeutics is a biotechnology company that is dedicated to revolutionizing drug discovery and development. The company combines deep drug discovery, development expertise, and technological breakthroughs to unlock highly validated but previously undruggable targets. Jnana's mission is to develop innovative therapies for patients with unmet medical needs.
The company was founded in 2015 by a team of experienced scientists who recognized the need for new approaches to drug discovery. They believed that by combining their expertise in chemistry, biology, and technology, they could create a new paradigm for discovering drugs that would be more effective than traditional methods.
Jnana's approach is based on the concept of "transporters," which are proteins that control the movement of molecules into and out of cells. By targeting these transporters, Jnana can selectively deliver drugs to specific cells or tissues in the body. This approach has the potential to unlock highly validated but previously undruggable targets, which could lead to breakthrough therapies for diseases such as cancer, autoimmune disorders, and metabolic disorders.
One of Jnana's key technologies is its proprietary platform for identifying small molecules that selectively target transporters. This platform uses advanced computational methods to predict how small molecules will interact with transporters at a molecular level. By screening millions of compounds against hundreds of transporter targets simultaneously, Jnana can rapidly identify promising candidates for further development.
In addition to its transporter-based approach, Jnana also has expertise in other areas of drug discovery and development. The company has developed novel assays for measuring protein-protein interactions and has expertise in medicinal chemistry optimization.
Jnana's pipeline includes several programs targeting different disease areas. One program focuses on developing selective inhibitors of SLC6A20 (a transporter involved in amino acid metabolism) as a potential treatment for kidney disease. Another program aims at developing selective inhibitors against SLC38A9 (a transporter involved in nutrient sensing) as a potential treatment option against cancer.
Overall, Jnana Therapeutics represents an exciting new approach to drug discovery and development with enormous potential impact on human health worldwide!